Arbutus Biopharma Corp ABUS Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125

03:42 EDT 12 Oct 2019 | BioPortfolio Reports

Arbutus Biopharma Corp ABUS Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Arbutus Biopharma Corp Arbutus Biopharma, formerly Tekmira Pharmaceuticals Corporation, focuses on the discovery, development and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection HBV. Its pipeline includes capsid assembly inhibitors AB506, AB729 and AB452; AB729 a second generation RNAi therapeutics which is under development using Nacetylgalactosamine GalNAc delivery technology and AB452 a HBV RNA destabilizer. The company develops product candidates based on its lipid nanoparticle LNP delivery technology. Arbutus Biopharma also has anticancer, antiviral and metabolic programs through strategic alliance, research collaborations and licensing agreements. It operates in the US and Canada. Arbutus Biopharma is headquartered in Burnaby, British Columbia, Canada.

Arbutus Biopharma Corp Key Recent Developments

Aug 05,2019: Arbutus reports second quarter 2019 financial results and provides corporate update

Jul 23,2019: Veritas reaches a mutual settlement with Arbutus Biopharma

Jun 17,2019: Arbutus appoints William Collier as next president CEO and announces retirement of current President CEO, Mark J. Murray Ph.D.

May 06,2019: Arbutus reports first quarter 2019 financial results and provides corporate update

Mar 07,2019: Arbutus Reports fourth quarter and yearend 2018 financial results and describes recent clinical accomplishments and key 2019 objectives

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Arbutus Biopharma Corp ABUS Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125


More From BioPortfolio on "Arbutus Biopharma Corp ABUS Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...